| Literature DB >> 29483833 |
Qian Wang1, Furao Liu1, Meichao Zhang1, Pingting Zhou1, Ci Xu1, Yanyan Li1, Lei Bian1, Yuanhua Liu2, Yuan Yao3, Fei Wang4, Yong Fang5, Dong Li1.
Abstract
Neutrophils are the most important component of the innate immune system. Mechanistic understanding of the mechanism underlying neutrophil differentiation remains elusive. Using genome-wide RNA-seq, we identified genes whose expression is dramatically up-regulated during neutrophil differentiation. Among them is nucleotide-binding leucine-rich repeat and pyrindomain-containing receptor 12 (NLRP12), which plays a role in immune inflammatory responses. Genetic ablation of NLRP12 suppresses NF-κB inducing kinase (NIK) stabilization, RelB nuclear translocation and neutrophil differentiation in vitro. At a mechanistic level, NLRP12 inhibits the activity of mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinases (ERK1/2), relieves ERK1/2 suppression of NIK protein levels. Thus, NLRP12 enhances noncanonical NF-κB signaling through inhibition of ERK1/2 signaling, thereby promoting neutrophil differentiation.Entities:
Keywords: ERK1/2; NF-κB; NLRP12; myeloid progenitors; neutrophils differentiation
Mesh:
Substances:
Year: 2018 PMID: 29483833 PMCID: PMC5821036 DOI: 10.7150/ijbs.23231
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1NLRP12 regulates neutrophil differentiation from myeloid progenitors. (A) Schematic outline of a RNA-seq experiment to determine the genes that involved in neutrophil differentiation. (B) Increased or decreased genes that were screened as described in (A). (C) The expression levels of NLRP12 during neutrophil differentiation were analyzed by western blotting. (D-F) Two shRNAs target NLRP12 were introduced into the mEB8-ER cells, the cells were induced to differentiate in the presence of G-CSF (2 ng/mL, 3 days). The expression of NLRP12 in mEB8-ER cells with or without NLRP12 depletion was analyzed by western blotting (D). The differentiation level was test by Wright-Giemsa staining of the differentiated cells (E) and flow cytometry for CD11b+ and GR-1+ (F). (G) The expression of NLRP12 in mEB8 cells with or without NLRP12 overexpression was analyzed by western blotting. (H-I) The cells with or without NLRP12 overexpression were induced to differentiate in the presence of G-CSF (2ng/mL, 3 days). The differentiation level was test by Wright-Giemsa staining of the differentiated cells (H) and flow cytometry for GR-1+/GFP+ cells (I). Three separate experiments were conducted, and quantification of 3 replicates of a typical experiment. Each bar represents the mean ± SEM (error bars). All values were normalized to the level (=1) in control group. **p< 0.01 and ***p < 0.001.
Figure 2NLRP12 enhances noncanonical NF-κB signaling. (A-B) mEB8-ER cells with or without NLRP12 depletion were stimulated with G-CSF (2 ng/mL) for the times indicated. The expression of NIK in the whole cell lysates was analyzed by western blotting (A). Extracts from the nuclear and cytoplasmic fractions were analyzed by western blotting for RelB (B). (C) mEB8-ER cells treated with or without TNFα (10 ng/mL) were induced to differentiate in the presence of G-CSF, and extracts from the nuclear and cytoplasmic fractions were analyzed by western blotting for RelB. (D) Relative percentage of GR-1+ cells in the mEB8-ER cells with or without TNFα treatment, NLRP12 depletion, was measured by flow cytometry. (E) The expression of NIK in the mEB8 cells with or without MG-132 treatment, NLRP12 depletion, was measured by western blotting. Three separate experiments were conducted, and quantification of 3 replicates of a typical experiment. Each bar represents the mean ±SEM (error bars). All values were normalized to the level (=1) in cells of control group. **p< 0.01 and ***p < 0.001.
Figure 3NLRP12 inhibits MAPK activation. (A) mEB8-ER cells with or without NLRP12 depletion were stimulated with G-CSF (2 ng/mL) for the times indicated. The phosphorylation and total expression levels of ERK1/2 and p38 in the whole cell lysates were analyzed by western blotting. (B) mEB8-ER cells were treated with U0126 (10 μM), and the expressions levels of NLRP12, p-ERK1/2 and ERK1/2, were analyzed by western blotting. (C) Relative percentage of GR-1+ cells in mEB8 cells with or without NLRP12 depletion and U0126 treatment were measured by flow cytometry. (D) The expression of ERK1/2, in the normal differentiated mEB8-ER cells and NLRP12 deficiency cells with CHX (1 μg/mL) treatment were analyzed by western blotting. (E) mEB8-ER cells with or without NLRP12 depletion were treated with 10 μM U0126. The cells were then induced to differentiate in the presence of G-CSF (2 ng/mL). The expression of NIK, p-ERK1/2 and ERK1/2 were analyzed using western blotting. Three separate experiments were conducted, and quantification of 3 replicates of a typical experiment. Each bar represents the mean ±SEM (error bars). All values were normalized to the level (=1) in cells of control group. **p< 0.01 and ***p < 0.001.
Figure 4NLRP12 has a conserved function in primary HPCs.The expression levels of NLRP12 during neutrophil differentiation using Sca-1-negative and c-Kit-positive progenitors from the mouse bone marrow were analyzed by western blotting (A). Two shRNAs target NLRP12 were introduced into the cells during differentiation, and the expression of NLRP12 were analyzed by western blotting (B), relative percentage of CD11b+ and GR-1+ cells in each group were measured by flow cytometry (C). Three separate experiments were conducted, and quantification of 3 replicates of a typical experiment. Each bar represents the mean ±SEM (error bars). All values were normalized to the level (=1) in cells of control group. *p< 0.05, **p < 0.01 and ***p < 0.001.
Sequences of q-PCR primers were used
| Primer | Sequence |
|---|---|
| β-actin-F | 5'-GGCTGTATTCCCCTCCATCG-3' |
| β-actin-R | 5'-CCAGTTGGTAACAATGCCATGT-3' |
| CD11b-F | 5'-CCATGACCTTCCAAGAGAATGC-3' |
| CD11b-R | 5'-ACCGGCTTGTGCTGTAGTC-3' |
| GR-1-F | 5'-GACTTCCTGCAACACAACTACC-3' |
| GR-1-R | 5'-ACAGCATTACCAGTGATCTCAGT-3' |
| NLRP12-F | 5'-GGATGGCCTCTATCGACTGTC-3' |
| NLRP12-R | 5'-CCTCTGCAATCCCCAGGAATAA-3' |
| GCSFR-F | 5'-CTGATCTTCTTGCTACTCCCCA-3' |
| GCSFR-R | 5'-GGTGTAGTTCAAGTGAGGCAG-3' |
| CEBPα-F | 5'-AAACAACGCAACGTGGAGA-3' |
| CEBPα-R | 5'-GCGGTCATTGTCACTGGTC-3' |
| PU.1-F | 5'-TCTTCTGCACGGGGAGACAG-3' |
| PU.1-R | 5'-GGACGAGAACTGGAAGGTACC-3' |
| NIK-F | 5'-AACGACTCTCCCGCGAAGA-3' |
| NIK-R | 5'-CGGCAGTGACCGTTTTAACA-3' |
| ERK-F | 5'-CAGGTGTTCGACGTAGGGC-3' |
| ERK-R | 5'-TCTGGTGCTCAAAAGGACTGA-3' |